Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Penske Provides Business Update as Lockdown Restrictions Ease

Published 06/09/2020, 09:59 PM
Updated 07/09/2023, 06:31 AM

Penske Automotive PAG recently updated on the recoveries in its operations from the declines witnessed in March and April, as states continue to ease the shelter-in-place strategies and begin reopening processes, which were imposed due to the coronavirus outbreak.

In the United States, all automotive retail dealership sales and service operations have started to reopen. As lockdown orders impacted operations in April, new and used unit sales plummeted around 50%, and service and parts gross profit slumped 52% year over year. Significant progress was witnessed in May, with new and used unit sales surging 60%, and service and parts gross profit rising 28%, sequentially. However, new and used unit sales declined roughly 25%, and service and parts gross profit plunged 39%, year over year, in May.

The sales and service operations of the company’s North American commercial truck dealership have also reopened. While new and used unit sales were flat in April, the same decreased 20% in May, year on year, as the Class 8 heavy-duty truck market adjusted from its record level last year. On a same-store basis, new and used units dropped 39% year over year in April and 19% sequentially in May. Service and parts gross profit remains solid with fixed consumption being more than 120% and maintenance orders per day up 7% sequentially in May.

Further, all dealerships in the U.K. had closed in accordance with government order on Mar 24, 2020. Service and part operations resumed in mid-May, with most dealership showrooms reopening on Jun 1, 2020. Despite the lockdown, the company remotely delivered around 2,500 vehicles in May. In addition, the company’s U.K. dealership operations had more than 4,000 vehicles sold through e-commerce efforts, which are scheduled to be delivered this month. Sales have been strong since the resumption of operations and surged about 50% year over year during the first week of June.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

All dealerships and service operations in Germany, Italy, Spain and Australia have also begun operations and are increasing from week to week. In Australia, all operations are open and restrictions in the market are being gradually lifted. Mining, transportation, defense and power generation sectors remain resilient, and service revenues were up 8% sequentially in May.

In addition, every component of Penske Transportation Solutions (PTS) delivered positive outcomes in May. New contracts for full-service leases were on par compared with the prior-year period. Contracts for commercial rental utilization improved in May. Further, Penske Logistics continued robust activities in the grocery and home improvement sectors. Revenues from the automotive segment also began to show signs of recovery as OEMs restarted productions. PTS earnings more than tripled sequentially but were down 17% year over year in May.

Zacks Rank & Stocks to Consider

Penske currently carries a Zacks Rank #3 (Hold). Shares of Penske have depreciated 13.7%, year to date, compared with the industry’s decline of 11.2%.

Some better-ranked stocks in the same sector are Tesla (NASDAQ:TSLA), Inc. TSLA, Halfords Group Plc HLFDY and Niu Technologies (NASDAQ:NIU) NIU. While Tesla sports a Zacks Rank of 1 (Strong Buy), Halfords and Niu carry a Zack Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Shares of Tesla have soared 124.9%, year to date, as against the industry’s rise of 41.2%.

Shares of Halfords have rallied 14.3%, year to date, as against its industry’s decline of 6.3%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Shares of Niu have gained 38.2%, year to date, as against the industry’s decline of 6.4%.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Penske Automotive Group, Inc. (NYSE:PAG): Free Stock Analysis Report

Tesla, Inc. (TSLA): Free Stock Analysis Report

Halfords Group Plc (HLFDY): Free Stock Analysis Report

NIU TECHADR (NIU): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.